Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

J H M Schellens

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Neoplasms

Procedures

Concepts & Ideas

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
128
Beijnen, Jos
47
Rosing, Hilde
41
Verweij, Jaap
29
ten Bokkel Huinink, Wim
22
Planting, A S T
20
van Tellingen, Olaf
20
de Boer-Dennert, MM
17
Huitema, Alwin
15
Loos, Walter
14
Mathôt, Ron
14
van der Burg, M E L
13
Malingré, Mirte
12
Swart, M
11
Ma, J
11
Maliepaard, Marc

Sign-in to see all Coauthors

Publications

TOP 3
Lankheet A G; Hillebrand M J X; Langenberg M H G; Rosing H; Huitema A D R; Voest E E; Schellens J H M; Beijnen J H
A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Teunissen S F; Rosing H; Koornstra R H T; Linn S C; Schellens J H M; Schinkel A H; Beijnen J H
Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry.
Harmsen S; Meijerman I; Beijnen J H; Schellens J H M
Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of J H M Schellens (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Lankheet A G; Hillebrand M J X; Langenberg M H G; Rosing H; Huitema A D R; Voest E E; Schellens J H M; Beijnen J H
A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(29):3625-30.
2009: Teunissen S F; Rosing H; Koornstra R H T; Linn S C; Schellens J H M; Schinkel A H; Beijnen J H
Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(24):2519-29.
2009: Harmsen S; Meijerman I; Beijnen J H; Schellens J H M
Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor.
Cancer chemotherapy and pharmacology 2009;64(1):35-43.
2009: Schellens J H M; Grouls R; Guchelaar H J; Touw D J; Rongen G A; de Boer A; Van Bortel L M
The Dutch vision of clinical pharmacology.
Clinical pharmacology and therapeutics 2009;85(4):366-8.
2009: Brouwers E E M; Söhne M; Kuipers S; van Gorp E C M; Schellens J H M; Koks C H W; Beijnen J H; Huitema A D R
Ciprofloxacin strongly inhibits clozapine metabolism: two case reports.
Clinical drug investigation 2009;29(1):59-63.
2008: Appels N M G M; Bolijn M J; Chan K; Stephens T C; Hoctin-Boes G; Middleton M; Beijnen J H; de Bono J S; Harris A L; Schellens J H M
Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer.
British journal of cancer 2008;98(12):1951-8.
2008: Harmsen S; Koster A S; Beijnen J H; Schellens J H M; Meijerman I
Comparison of two immortalized human cell lines to study nuclear receptor-mediated CYP3A4 induction.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(6):1166-71.
2008: Zandvliet A S; Siegel-Lakhai W S; Beijnen J H; Copalu W; Etienne-Grimaldi M-C; Milano G; Schellens J H M; Huitema A D R
PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression.
Clinical pharmacology and therapeutics 2008;83(6):829-39.
2008: Hoebers F J P; Pluim D; Hart A A M; Verheij M; Balm A J M; Fons G; Rasch C R N; Schellens J H M; Stalpers L J A; Bartelink H; Begg A C
Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.
Cancer chemotherapy and pharmacology 2008;61(6):1075-81.
2008: Siegel-Lakhai W S; Zandvliet A S; Huitema A D R; Tibben M M; Milano G; Girre V; Diéras V; King A; Richmond E; Wanders J; Beijnen J H; Schellens J H M
A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours.
British journal of cancer 2008;98(8):1320-6.
2007: Joerger M; Huitema A D R; Huizing M T; Willemse P H B; de Graeff A; Rosing H; Schellens J H M; Beijnen J H; Vermorken J B
Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study.
British journal of clinical pharmacology 2007;64(5):622-33.
2007: Veltkamp S A; Rosing H; Huitema A D R; Fetell M R; Nol A; Beijnen J H; Schellens J H M
Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours.
Cancer chemotherapy and pharmacology 2007;60(5):635-42.
2007: Marchetti S; Schellens J H M
The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials.
British journal of cancer 2007;97(5):577-81.
2007: Brouwers E E M; Huitema A D R; Bakker E N; Douma J W; Schimmel K J M; van Weringh G; de Wolf P J; Schellens J H M; Beijnen J H
Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry.
International archives of occupational and environmental health 2007;80(8):689-99.
2007: Beumer J H; Garner R C; Cohen M B; Galbraith S; Duncan G F; Griffin T; Beijnen J H; Schellens J H M
Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.
Investigational new drugs 2007;25(4):327-34.
2007: Harmsen S; Meijerman I; Beijnen J H; Schellens J H M
The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology.
Cancer treatment reviews 2007;33(4):369-80.
2007: Kuppens I E L M; Witteveen P O; Schot M; Schuessler V M; Daehling A; Beijnen J H; Voest E E; Schellens J H M
Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors.
Investigational new drugs 2007;25(3):227-35.
2007: Keizer R J; Huitema A D R; Damen C W N; Schellens J H M; Beijnen J H
[The pharmacokinetics of monoclonal antibodies]
Nederlands tijdschrift voor geneeskunde 2007;151(12):683-8.
2007: Schellens J H M; Beijnen J H
[Management recommendations in patients with methotrexate intoxication]
Nederlands tijdschrift voor geneeskunde 2007;151(6):337-41.
2007: Kemper E M; van Kan H J M; Speelman P; de Gans K; Beijnen J H; Schellens J H M
[Severe phenytoin intoxication in patients with hypoalbuminaemia]
Nederlands tijdschrift voor geneeskunde 2007;151(2):138-41.
2007: Veltkamp S A; Alderden-Los C; Sharma A; Rosing H; Beijnen J H; Schellens J H M
A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
Cancer chemotherapy and pharmacology 2007;59(1):43-50.
2006: Veltkamp S A; Hillebrand M J X; Rosing H; Jansen R S; Wickremsinhe E R; Perkins E J; Schellens J H M; Beijnen J H
Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.
Journal of mass spectrometry : JMS 2006;41(12):1633-42.
2006: Helgason H H; Kruijtzer C M F; Huitema A D R; Marcus S G; ten Bokkel Huinink W W; Schot M E; Schornagel J H; Beijnen J H; Schellens J H M
Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer.
British journal of cancer 2006;95(7):794-800.
2006: Brouwers E E M; Tibben M M; Rosing H; Hillebrand M J X; Joerger M; Schellens J H M; Beijnen J H
Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.
Journal of mass spectrometry : JMS 2006;41(9):1186-94.
2006: Veltkamp S A; Thijssen B; Garrigue J S; Lambert G; Lallemand F; Binlich F; Huitema A D R; Nuijen B; Nol A; Beijnen J H; Schellens J H M
A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer.
British journal of cancer 2006;95(6):729-34.
2006: Joerger Markus; Huitema A D R; Boogerd W; van der Sande J J; Schellens J H M; Beijnen J H
Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.
Basic & clinical pharmacology & toxicology 2006;99(2):133-40.
2006: Joerger M; Bosch T M; Doodeman V D; Beijnen J H; Smits P H M; Schellens J H M
Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers.
European journal of clinical pharmacology 2006;62(8):681-4.
2006: van den Berg J H; Beijnen J H; Balm A J M; Schellens J H M
Future opportunities in preventing cisplatin induced ototoxicity.
Cancer treatment reviews 2006;32(5):390-7.
2006: Joerger M; Huitema A D R; van den Bongard H J G D; Baas P; Schornagel J H; Schellens J H M; Beijnen J H
Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.
British journal of clinical pharmacology 2006;62(1):71-80.
2006: Vlaming M L H; Mohrmann K; Wagenaar E; de Waart D R; Elferink R P J Oude; Lagas J S; van Tellingen O; Vainchtein L D; Rosing H; Beijnen J H; Schellens J H M; Schinkel A H
Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice.
The Journal of pharmacology and experimental therapeutics 2006;318(1):319-27.
2006: van den Broek I; Sparidans R W; Huitema A D R; Schellens J H M; Beijnen J H
Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006;837(1-2):49-58.
2006: Gast M C W; Bonfrer J M G; van Dulken E J; de Kock L; Rutgers E J Th; Schellens J H M; Beijnen J H
SELDI-TOF MS serum protein profiles in breast cancer: assessment of robustness and validity.
Cancer biomarkers : section A of Disease markers 2006;2(6):235-48.
2006: Bosch T M; Doodeman V D; Smits P H M; Meijerman I; Schellens J H M; Beijnen J H
Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population.
Molecular diagnosis & therapy 2006;10(3):175-85.
2005: Siegel-Lakhai W S; Crul M; Zhang S; Sparidans R W; Pluim D; Howes A; Solanki B; Beijnen J H; Schellens J H M
Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.
British journal of cancer 2005;93(11):1222-9.
2005: Beumer J H; Rademaker-Lakhai J M; Rosing H; Lopez-Lazaro L; Beijnen J H; Schellens J H M
Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.
Investigational new drugs 2005;23(5):429-36.
2005: Lekkerkerker J F F; Schobben A F A M; van Dissel J T; Hekster Y A; Hoes A W; Mulder G J; Neef C; Peeters M F; van Ree J M; Rosmalen C F H; Schellekens H; Schellens J H M; Silberbusch J
[Selective serotonin reuptake inhibitors (SSRI's) are not indicated for children and adolescents with depression]
Nederlands tijdschrift voor geneeskunde 2005;149(33):1870-1; author reply 1871-2.
2005: Brouwers E E M; Tibben M M; Joerger M; van Tellingen O; Rosing H; Schellens J H M; Beijnen J H
Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry.
Analytical and bioanalytical chemistry 2005;382(7):1484-90.
2005: Kuppens I E L M; van Maanen M J; Rosing H; Schellens J H M; Beijnen J H
Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry.
Biomedical chromatography : BMC 2005;19(5):355-61.
2005: Beumer J H; Schellens J H M; Beijnen J H
Hepatotoxicity and metabolism of trabectedin: a literature review.
Pharmacological research : the official journal of the Italian Pharmacological Society 2005;51(5):391-8.
2005: Joerger M; Huitema A D R; Meenhorst P L; Schellens J H M; Beijnen J H
Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Cancer chemotherapy and pharmacology 2005;55(5):488-96.
2005: Kuppens I E L M; Bosch T M; van Maanen M J; Rosing H; Fitzpatrick A; Beijnen J H; Schellens J H M
Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).
Cancer chemotherapy and pharmacology 2005;55(1):72-8.
2005: Kuppens Isa E L M; Breedveld P; Beijnen J H; Schellens J H M
Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application.
Cancer investigation 2005;23(5):443-64.
2004: Schoemaker N E; Kuppens I E L M; Moiseyenko V; Glimelius B; Kjaer M; Starkhammer H; Richel D J; Smaaland R; Bertelsen K; Poulsen J P; Voznyi E; Norum J; Fennelly D; Tveit K M; Garin A; Gruia G; Mourier A; Sibaud D; Lefebvre P; Beijnen J H; Schellens J H M; ten Bokkel Huinink W W
A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.
British journal of cancer 2004;91(8):1434-41.
2004: Joerger M; Schellens J H M; Beijnen J H
Therapeutic drug monitoring of non-anticancer drugs in cancer patients.
Methods and findings in experimental and clinical pharmacology 2004;26(7):531-45.
2004: Calvet L; Santos A; Valent A; Terrier-Lacombe M-J; Opolon P; Merlin J-L; Aubert G; Morizet J; Schellens J H M; Bénard J; Vassal G
No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan.
British journal of cancer 2004;91(6):1205-12.
2004: Rothbarth J; Tollenaar R A E M; Schellens J H M; Nortier J W R; Kool L J Schultze; Kuppen P J K; Mulder G J; van de Velde C J H
Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives.
European journal of cancer (Oxford, England : 1990) 2004;40(12):1812-24.
2004: Stokvis E; Rosing H; López-Lázaro L; Schellens J H M; Beijnen J H
Switching from an analogous to a stable isotopically labeled internal standard for the LC-MS/MS quantitation of the novel anticancer drug Kahalalide F significantly improves assay performance.
Biomedical chromatography : BMC 2004;18(6):400-2.
2004: Kerbusch T; Groenewegen G; Mathôt R A A; Herben V M M; ten Bokkel Huinink W W; Swart M; Ambaum B; Rosing H; Jansen S; Voest E E; Beijnen J H; Schellens J H M
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.
British journal of cancer 2004;90(12):2268-77.
2004: Stokvis E; Rosing H; Crul M; Rieser M J; Heck A J R; Schellens J H M; Beijnen J H
Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.
Journal of mass spectrometry : JMS 2004;39(3):277-88.
2003: van Kesteren Ch; de Vooght M M M; López-Lázaro L; Mathôt R A A; Schellens J H M; Jimeno J M; Beijnen J H
Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
Anti-cancer drugs 2003;14(7):487-502.
2003: Bardelmeijer H A; Buckle T; Ouwehand M; Beijnen J H; Schellens J H M; van Tellingen O
Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples.
Laboratory animals 2003;37(3):181-7.
2003: Bongard H J G D van den; Pluim D; Waardenburg R C A M van; Ravic M; Beijnen J H; Schellens J H M
In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood.
Anti-cancer drugs 2003;14(6):405-10.
2003: Chollet P; Schöffski P; Weigang-Köhler K; Schellens J H M; Cure H; Pavlidis N; Grünwald V; De Boer R; Wanders J; Fumoleau P;
Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).
European journal of cancer (Oxford, England : 1990) 2003;39(9):1264-70.
2003: van Kesteren Ch; Mathôt R A A; Beijnen J H; Schellens J H M
Pharmacokinetic-pharmacodynamic guided trial design in oncology.
Investigational new drugs 2003;21(2):225-41.
2003: Stokvis E; Nan-Offeringa L; Rosing H; López-Lázaro L; Aceña J L; Miranda E; Lyubimov A; Levine B S; D'Aleo C; Schellens J H M; Beijnen J H
Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry.
Journal of mass spectrometry : JMS 2003;38(5):548-54.
2003: Terret C; Zanetta S; Roché H; Schellens J H M; Faber M N; Wanders J; Ravic M; Droz J P;
Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG).
European journal of cancer (Oxford, England : 1990) 2003;39(8):1097-104.
2003: Van den Brande J; Schöffski P; Schellens J H M; Roth A D; Duffaud F; Weigang-Köhler K; Reinke F; Wanders J; de Boer R F; Vermorken J B; Fumoleau P
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.
British journal of cancer 2003;88(5):648-53.
2003: Schellens J H M; Planting A S T; van Zandwijk N; Ma J; Maliepaard M; van der Burg M E L; de Boer-Dennert M; Brouwer E; van der Gaast A; van den Bent M J; Verweij J
Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer.
British journal of cancer 2003;88(6):814-21.
2003: Kruijtzer C M F; Boot H; Beijnen J H; Lochs H L; Parnis F X; Planting A S T; Pelgrims J M G; Williams R; Mathôt R A A; Rosing H; Schot M E; Van Tinteren H; Schellens J H M
Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(2):197-204.
2002: Crul M; van Waardenburg R C A M; Beijnen J H; Schellens J H M
DNA-based drug interactions of cisplatin.
Cancer treatment reviews 2002;28(6):291-303.
2002: Kruijtzer C M F; Schellens J H M; Mezger J; Scheulen M E; Keilholz U; Beijnen J H; Rosing H; Mathôt R A A; Marcus S; van Tinteren H; Baas P
Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(23):4508-16.
2002: van Kesteren Charlotte; Mathôt R A A; Raymond E; Armand J P; Fumoleau P; Punt C; Ravic M; Wanders J; Beijnen J H; Schellens J H M;
Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).
British journal of clinical pharmacology 2002;54(5):463-71.
2002: Van Kesteren Ch; Mathôt R A A; Raymond E; Armand J P; Dittrich Ch; Dumez H; Roché H; Droz J P; Punt C; Ravic M; Wanders J; Beijnen J H; Fumoleau P; Schellens J H M;
Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(19):4065-73.
2002: Stokvis E; Rosing H; López-Lázaro L; Rodriguez I; Jimeno J M; Supko J G; Schellens J H M; Beijnen J H
Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry.
Journal of mass spectrometry : JMS 2002;37(9):992-1000.
2002: Schoemaker N E; van Kesteren C; Rosing H; Jansen S; Swart M; Lieverst J; Fraier D; Breda M; Pellizzoni C; Spinelli R; Grazia Porro M; Beijnen J H; Schellens J H M; ten Bokkel Huinink W W
A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin.
British journal of cancer 2002;87(6):608-14.
2002: Raymond E; ten Bokkel Huinink W W; Taïeb J; Beijnen J H; Faivre S; Wanders J; Ravic M; Fumoleau P; Armand J P; Schellens J H M;
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(16):3508-21.
2002: Crul M; Rosing H; de Klerk G J; Dubbelman R; Traiser M; Reichert S; Knebel N G; Schellens J H M; Beijnen J H; ten Bokkel Huinink W W
Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.
European journal of cancer (Oxford, England : 1990) 2002;38(12):1615-21.
2002: van den Bongard H J G D; Mathôt R A A; van Tellingen O; Schellens J H M; Beijnen J H
A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
Cancer chemotherapy and pharmacology 2002;50(1):16-24.
2002: Tibben M M; Rademaker-Lakhai J M; Rice J R; Stewart D R; Schellens J H M; Beijnen J H
Determination of total platinum in plasma and plasma ultrafiltrate, from subjects dosed with the platinum-containing N-(2-hydroxypropyl)methacrylamide copolymer AP5280, by use of graphite-furnace Zeeman atomic-absorption spectrometry.
Analytical and bioanalytical chemistry 2002;373(4-5):233-6.
2002: Kruijtzer C M F; Beijnen J H; Rosing H; ten Bokkel Huinink W W; Schot M; Jewell R C; Paul E M; Schellens J H M
Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(13):2943-50.
2002: Crul M; de Klerk G J; Swart M; van't Veer L J; de Jong D; Boerrigter L; Palmer P A; Bol C J; Tan H; de Gast G C; Beijnen J H; Schellens J H M
Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(11):2726-35.
2002: Bartelink H; Schellens J H M; Verheij M
[The concomitant use of radiotherapy and chemotherapy for the treatment of solid malignant tumors]
Nederlands tijdschrift voor geneeskunde 2002;146(11):504-8.
2002: Schellens J H M; Heinrich B; Lehnert M; Gore M E; Kaye S B; Dombernowsky P; Paridaens R; van Oosterom A T; Verweij J; Loos W J; Calvert H; Pavlidis N; Cortes-Funes H; Wanders J; Roelvink M; Sessa C; Selinger K; Wissel P S; Gamucci T; Hanauske A R
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.
Investigational new drugs 2002;20(1):83-93.
2002: Crul M; de Klerk G J; Swart M; Weiner L; Palmer P A; Bol C J; Beijnen J H; Schellens J H M
Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors.
European journal of drug metabolism and pharmacokinetics 2002;27(1):61-5.
2002: Bartelink H; Schellens J H M; Verheij M
The combined use of radiotherapy and chemotherapy in the treatment of solid tumours.
European journal of cancer (Oxford, England : 1990) 2002;38(2):216-22.
2002: Caponigro F; Dittrich C; Sorensen J B; Schellens J H M; Duffaud F; Paz Ares L; Lacombe D; de Balincourt C; Fumoleau P
Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2002;38(1):70-4.
2002: Kruijtzer C M F; Beijnen J H; Schellens J H M
Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview.
The oncologist 2002;7(6):516-30.
2001: van Kesteren C; Mathjt R A; López-Lázaro L; Cvitkovic E; Taamma A; Jimeno J M; Guzman C; Schellens J H; Misset J L; Brain E; Hillebrand M J; Rosing H; Beijnen J H
A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.
Cancer chemotherapy and pharmacology 2001;48(6):459-66.
2001: Malingré M M; Schellens J H; Van Tellingen O; Ouwehand M; Bardelmeijer H A; Rosing H; Koopman F J; Schot M E; Ten Bokkel Huinink W W; Beijnen J H
The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
British journal of cancer 2001;85(10):1472-7.
2001: Bardelmeijer H A; Ouwehand M; Beijnen J H; Schellens J H; van Tellingen O
Determination of cyclosporin A in human and mouse plasma by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 2001;763(1-2):201-6.
2001: Schoemaker N E; Frigerio E; Fraier D; Schellens J H; Rosing H; Jansen S; Beijnen J H
High-performance liquid chromatographic analysis for the determination of a novel polymer-bound camptothecin derivative (MAG-camptothecin) and free camptothecin in human plasma.
Journal of chromatography. B, Biomedical sciences and applications 2001;763(1-2):173-83.
2001: Kerbusch T; Mathjt R A; Keizer H J; Ouwerkerk J; Rodenhuis S; Schellens J H; Beijnen J H
Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma.
European journal of clinical pharmacology 2001;57(6-7):467-77.
2001: Schellens J H; Planting A S; Ma J; Maliepaard M; de Vos A; de Boer Dennert M; Verweij J
Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer.
Anti-cancer drugs 2001;12(8):667-75.
2001: Sparidans R W; Rosing H; Hillebrand M J; López-Lázaro L; Jimeno J M; Manzanares I; van Kesteren C; Cvitkovic E; van Oosterom A T; Schellens J H; Beijnen J H
Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man.
Anti-cancer drugs 2001;12(8):653-66.
2001: Kemper E M; Jansen B; Brouwer K R; Schellens J H; Beijnen J H; van Tellingen O
Bioanalysis and preliminary pharmacokinetics of the acridonecarboxamide derivative GF120918 in plasma of mice and humans by ion-pairing reversed-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 2001;759(1):135-43.
2001: Malingré M M; Ten Bokkel Huinink W W; Duchin K; Schellens J H; Beijnen J H
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel.
Anti-cancer drugs 2001;12(7):591-3.
2001: Schellens J H; Dombernowsky P; Cassidy J; Epelbaum R; Dirix L; Cox E H; Wanders J; Calabresi F; Paridaens R; Monfardini S; Wolff J; Loos W J; Verweij J; Pavlidis N; Hanauske A R;
Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9.
Anti-cancer drugs 2001;12(7):583-90.
2001: Sparidans R W; Stokvis E; Jimeno J M; López-Lázaro L; Schellens J H; Beijnen J H
Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F.
Anti-cancer drugs 2001;12(7):575-82.
2001: Malingré M M; Ten Bokkel Huinink W W; Mackay M; Schellens J H; Beijnen J H
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel.
European journal of clinical pharmacology 2001;57(4):305-7.
2001: Kerbusch T; Mathôt R A; Keizer H J; Kaijser G P; Schellens J H; Beijnen J H
Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(7):967-75.
2001: van den Bongard H J; Mathjt R A; Boogerd W; Schornagel J H; Soesan M; Schellens J H; Beijnen J H
Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure.
Cancer chemotherapy and pharmacology 2001;47(6):537-40.
2001: Malingré M M; Beijnen J H; Schellens J H
Oral delivery of taxanes.
Investigational new drugs 2001;19(2):155-62.
2001: Nuijen B; Bouma M; Schellens J H; Beijnen J H
Progress in the development of alternative pharmaceutical formulations of taxanes.
Investigational new drugs 2001;19(2):143-53.
2001: Malingré M M; Beijnen J H; Rosing H; Koopman F J; van Tellingen O; Duchin K; Ten Bokkel Huinink W W; Swart M; Lieverst J; Schellens J H
A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
Cancer chemotherapy and pharmacology 2001;47(4):347-54.
2001: Malingré M M; Beijnen J H; Rosing H; Koopman F J; van Tellingen O; Duchin K; ten Bokkel Huinink W W; Swart M; Lieverst J; Schellens J H
The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel.
Anti-cancer drugs 2001;12(4):351-8.
2001: Meerum Terwogt J M; ten Bokkel Huinink W W; Schellens J H; Schot M; Mandjes I A; Zurlo M G; Rocchetti M; Rosing H; Koopman F J; Beijnen J H
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel.
Anti-cancer drugs 2001;12(4):315-23.
2001: Maliepaard M; van Gastelen M A; Tohgo A; Hausheer F H; van Waardenburg R C; de Jong L A; Pluim D; Beijnen J H; Schellens J H
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(4):935-41.
2001: Maliepaard M; Scheffer G L; Faneyte I F; van Gastelen M A; Pijnenborg A C; Schinkel A H; van De Vijver M J; Scheper R J; Schellens J H
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
Cancer research 2001;61(8):3458-64.
2001: Crul M; de Klerk G J; Beijnen J H; Schellens J H
Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
Anti-cancer drugs 2001;12(3):163-84.
2001: Crul M; van den Bongard H J; Tibben M M; van Tellingen O; Sava G; Schellens J H; Beijnen J H
Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry.
Fresenius' journal of analytical chemistry 2001;369(5):442-5.
2001: Malingré M M; Richel D J; Beijnen J H; Rosing H; Koopman F J; Ten Bokkel Huinink W W; Schot M E; Schellens J H
Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):1160-6.
2001: Kerbusch T; de Kraker J; Keizer H J; van Putten J W; Groen H J; Jansen R L; Schellens J H; Beijnen J H
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
Clinical pharmacokinetics 2001;40(1):41-62.
2001: Huitema A D; Mathôt R A; Tibben M M; Schellens J H; Rodenhuis S; Beijnen J H
Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.
British journal of clinical pharmacology 2001;51(1):61-70.
2001: Malingré M M; Beijnen J H; Rosing H; Koopman F J; Jewell R C; Paul E M; Ten Bokkel Huinink W W; Schellens J H
Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
British journal of cancer 2001;84(1):42-7.
2000: van Kesteren C; Cvitkovic E; Taamma A; López-Lázaro L; Jimeno J M; Guzman C; Math t R A; Schellens J H; Misset J L; Brain E; Hillebrand M J; Rosing H; Beijnen J H
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4725-32.
2000: Schellens J H; Malingré M M; Kruijtzer C M; Bardelmeijer H A; van Tellingen O; Schinkel A H; Beijnen J H
Modulation of oral bioavailability of anticancer drugs: from mouse to man.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2000;12(2):103-10.
2000: Malingré M M; Schellens J H; van Tellingen O; Rosing H; Koopman F J; Duchin K; Huinink W W; Swart M; Beijnen J H
Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration.
Anti-cancer drugs 2000;11(10):813-20.
2000: Nuijen B; Bouma M; Manada C; Jimeno J M; Schellens J H; Bult A; Beijnen J H
Pharmaceutical development of anticancer agents derived from marine sources.
Anti-cancer drugs 2000;11(10):793-811.
2000: van den Bongard H J; Mathôt R A; Beijnen J H; Schellens J H
Pharmacokinetically guided administration of chemotherapeutic agents.
Clinical pharmacokinetics 2000;39(5):345-67.
2000: Bardelmeijer H A; Beijnen J H; Brouwer K R; Rosing H; Nooijen W J; Schellens J H; van Tellingen O
Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(11):4416-21.
2000: Meerum Terwogt J; van Tellingen O; Nannan Panday V R; Huizing M T; Schellens J H; ten Bokkel Huinink W W; Boschma M U; Giaccone G; Veenhof C H; Beijnen J H
Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients.
Anti-cancer drugs 2000;11(9):687-94.
2000: Jonker J W; Smit J W; Brinkhuis R F; Maliepaard M; Beijnen J H; Schellens J H; Schinkel A H
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Journal of the National Cancer Institute 2000;92(20):1651-6.
2000: Huitema A D; Smits K D; Mathôt R A; Schellens J H; Rodenhuis S; Beijnen J H
The clinical pharmacology of alkylating agents in high-dose chemotherapy.
Anti-cancer drugs 2000;11(7):515-33.
2000: Bardelmeijer H A; van Tellingen O; Schellens J H; Beijnen J H
The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.
Investigational new drugs 2000;18(3):231-41.
2000: Gamucci T; Paridaens R; Heinrich B; Schellens J H; Pavlidis N; Verweij J; Sessa C; Kaye S; Roelvink M; Wanders J; Hanauske A
Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(7):793-7.
2000: Kuiper R A; Malingré M M; Beijnen J H; Schellens J H
Cyclosporine-induced anaphylaxis.
The Annals of pharmacotherapy 2000;34(7-8):858-61.
2000: Huitema A D; Mathôt R A; Tibben M M; Schellens J H; Rodenhuis S; Beijnen J H
Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
Clinical pharmacology and therapeutics 2000;67(6):621-30.
2000: Malingré M M; Terwogt J M; Beijnen J H; Rosing H; Koopman F J; van Tellingen O; Duchin K; Huinink W W; Swart M; Lieverst J; Schellens J H
Phase I and pharmacokinetic study of oral paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(12):2468-75.
2000: Kerbusch T; Huitema A D; Ouwerkerk J; Keizer H J; Mathôt R A; Schellens J H; Beijnen J H
Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.
British journal of clinical pharmacology 2000;49(6):555-61.
2000: Scheffer G L; Maliepaard M; Pijnenborg A C; van Gastelen M A; de Jong M C; Schroeijers A B; van der Kolk D M; Allen J D; Ross D D; van der Valk P; Dalton W S; Schellens J H; Scheper R J
Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.
Cancer research 2000;60(10):2589-93.
2000: Kruijtzer CMF; Verweij J; Schellens J H; Beijnen J H; Pronk L; Bo M; Lustig V; van Tinteren H; Mackay M; Ten Bokkel Huinink W W
Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands.
Anti-cancer drugs 2000;11(4):249-55.
2000: Meerum Terwogt J M; Tibben M M; Welbank H; Schellens J H; Beijnen J H
Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry.
Fresenius' journal of analytical chemistry 2000;366(3):298-302.
2000: Schellens J H; Maliepaard M; Scheper R J; Scheffer G L; Jonker J W; Smit J W; Beijnen J H; Schinkel A H
Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
Annals of the New York Academy of Sciences 2000;922():188-94.
2000: Kruijtzer C M; Beijnen J H; Swart M; Schellens J H
Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma). A case report and review of the literature.
Cancer chemotherapy and pharmacology 2000;45(5):428-31.
2000: Rosing H; Lustig V; van Warmerdam L J; Huizing M T; ten Bokkel Huinink W W; Schellens J H; Rodenhuis S; Bult A; Beijnen J H
Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.
Cancer chemotherapy and pharmacology 2000;45(3):213-8.
1999: Meerum Terwogt J M; Malingré M M; Beijnen J H; ten Bokkel Huinink W W; Rosing H; Koopman F J; van Tellingen O; Swart M; Schellens J H
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(11):3379-84.
1999: Pluim D; Maliepaard M; van Waardenburg R C; Beijnen J H; Schellens J H
32P-postlabeling assay for the quantification of the major platinum-DNA adducts.
Analytical biochemistry 1999;275(1):30-8.
1999: Nannan Panday V R; van Warmerdam L J; Huizing M T; Ten Bokkel Huinink W W; Schellens J H; Beijnen J H
A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel.
Journal of cancer research and clinical oncology 1999;125(11):615-20.
1999: Planting A S; Schellens J H; van der Burg M E; de Boer-Dennert M; Winograd B; Stoter G; Verweij J
Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors.
Anti-cancer drugs 1999;10(9):821-7.
1999: Verschraagen M; Koks C H; Schellens J H; Beijnen J H
P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil.
Pharmacological research : the official journal of the Italian Pharmacological Society 1999;40(4):301-6.
1999: van Tellingen O; Huizing M T; Panday V R; Schellens J H; Nooijen W J; Beijnen J H
Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
British journal of cancer 1999;81(2):330-5.
1999: Maliepaard M; van Gastelen M A; de Jong L A; Pluim D; van Waardenburg R C; Ruevekamp-Helmers M C; Floot B G; Schellens J H
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Cancer research 1999;59(18):4559-63.
1999: Herben V M; Rosing H; ten Bokkel Huinink W W; van Zomeren D M; Batchelor D; Doyle E; Beusenberg F D; Beijnen J H; Schellens J H
Oral topotecan: bioavailablity and effect of food co-administration.
British journal of cancer 1999;80(9):1380-6.
1999: Panday V R; ten Bokkel Huinink W W; Vermorken J B; Rosing H; Koopman F J; Swart M; Schellens J H; Beijnen J H
Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.
Pharmacological research : the official journal of the Italian Pharmacological Society 1999;40(1):67-74.
1999: Herben V M; van Gijn R; Schellens J H; Schot M; Lieverst J; Hillebrand M J; Schoemaker N E; Porro M G; Beijnen J H; ten Bokkel Huinink W W
Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1906-14.
1999: Herben V M; Schellens J H; Swart M; Gruia G; Vernillet L; Beijnen J H; ten Bokkel Huinink W W
Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1897-905.
1999: Terwogt J M; Schellens J H; Huinink W W; Beijnen J H
Clinical pharmacology of anticancer agents in relation to formulations and administration routes.
Cancer treatment reviews 1999;25(2):83-101.
1999: van Zuylen L; Schellens J H; Goey S H; Pronk L C; de Boer-Dennert M M; Loos W J; Ma J; Stoter G; Verweij J
Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients with non-small cell lung cancer.
Anti-cancer drugs 1999;10(4):361-8.
1999: Rosing H; van Zomeren D M; Doyle E; ten Bokkel W W; Schellens J H; Bult A; Beijnen J H
Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods.
Journal of chromatography. B, Biomedical sciences and applications 1999;727(1-2):191-203.
1999: Herben V M; Panday V R; Richel D J; Schellens J H; van der Vange N; Rosing H; Beusenberg F D; Hearn S; Doyle E; Beijnen J H; ten Bokkel Huinink W W
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):747-55.
1999: de Graaff M; Maliepaard M; Pluim D; Floot B J; Slaper-Cortenbach I C; Schellens J H
In vitro antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM.
Anti-cancer drugs 1999;10(2):213-8.
1999: Gerrits C J; Schellens J H; Burris H; Eckardt J R; Planting A S; van der Burg M E; Rodriguez G I; Loos W J; van Beurden V; Hudson I; Von Hoff D D; Verweij J
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(1):69-75.
1999: Nannan Panday V R; de Wit R; Schornagel J H; Schot M; Rosing H; Lieverst J; ten Bokkel Huinink W W; Schellens J H; Beijnen J H
Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.
Cancer chemotherapy and pharmacology 1999;44(4):349-53.
1999: Panday V R; van Warmerdam L J; Huizing M T; Rodenhuis S; Schellens J H; Beijnen J H
A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen.
Cancer chemotherapy and pharmacology 1999;43(5):435-8.
1998: Crommentuyn K M; Schellens J H; van den Berg J D; Beijnen J H
In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide.
Cancer treatment reviews 1998;24(5):345-66.
1998: Panday V R; ten Bokkel Huinink W W; Rosing H; Koopman F J; Hillebrand M J; Dubbelman R C; van Tellingen O; Schellens J H; Beijnen J H
Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer.
Anti-cancer drugs 1998;9(8):665-73.
1998: Panday V R; Huizing M T; van Warmerdam L J; Dubbelman R C; Mandjes I; Schellens J H; Huinink W W; Beijnen J H
Pharmacologic study of 3-hour 135 mg M-2 paclitaxel in platinum pretreated patients with advanced ovarian cancer.
Pharmacological research : the official journal of the Italian Pharmacological Society 1998;38(3):231-6.
1998: Herben V M; Ten Bokkel Huinink W W; Schellens J H; Beijnen J H
Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.
Pharmacy world & science : PWS 1998;20(4):161-72.
1998: Gerrits C J; Burris H; Schellens J H; Planting A S; van den Burg M E; Rodriguez G I; van Beurden V; Loos W J; Hudson I; Fields S; Verweij J; von Hoff D D
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 1998;34(7):1030-5.
1998: Ma J; Maliepaard M; Nooter K; Loos W J; Kolker H J; Verweij J; Stoter G; Schellens J H
Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
British journal of cancer 1998;77(10):1645-52.
1998: Gerrits C J; Burris H; Schellens J H; Eckardt J R; Planting A S; van der Burg M E; Rodriguez G I; Loos W J; van Beurden V; Hudson I; Fields S; Von Hoff D D; Verweij J
Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(5):1153-8.
1998: Pronk L C; Schrijvers D; Schellens J H; de Bruijn E A; Planting A S; Locci-Tonelli D; Groult V; Verweij J; van Oosterom A T
Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.
Seminars in oncology 1998;25(1 Suppl 2):23-8.
1998: Kuiper R A; Schellens J H; Blijham G H; Beijnen J H; Voest E E
Clinical research on antiangiogenic therapy.
Pharmacological research : the official journal of the Italian Pharmacological Society 1998;37(1):1-16.
1998: Nannan Panday V R; van Warmerdam L J; Huizing M T; Ten Bokkel Huinink W W; Vermorken J B; Giaccone G; Veenhof C H; Schellens J H; Beijnen J H
Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens.
Clinical drug investigation 1998;15(4):327-35.
1998: Ma J; Maliepaard M; Nooter K; Boersma A W; Verweij J; Stoter G; Schellens J H
Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.
Cancer chemotherapy and pharmacology 1998;41(4):307-16.
1998: Pronk L C; Schrijvers D; Schellens J H; de Bruijn E A; Planting A S; Locci-Tonelli D; Groult V; Verweij J; van Oosterom A T
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
British journal of cancer 1998;77(1):153-8.
1998: Ma J; Maliepaard M; Kolker H J; Verweij J; Schellens J H
Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1.
Cancer chemotherapy and pharmacology 1998;41(3):186-92.
1997: Crul M; Schellens J H; Beijnen J H; Maliepaard M
Cisplatin resistance and DNA repair.
Cancer treatment reviews 1997;23(5-6):341-66.
1997: Loos W J; Sparreboom A; Verweij J; Nooter K; Stoter G; Schellens J H
Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 1997;694(2):435-41.
1997: Creemers G J; Gerrits C J; Eckardt J R; Schellens J H; Burris H A; Planting A S; Rodriguez G I; Loos W J; Hudson I; Broom C; Verweij J; Von Hoff D D
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):1087-93.
1997: Pronk L C; Schellens J H; Planting A S; van den Bent M J; Hilkens P H; van der Burg M E; de Boer-Dennert M; Ma J; Blanc C; Harteveld M; Bruno R; Stoter G; Verweij J
Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):1071-9.
1997: Schellens J H; Van de Vrie W; Loos W J; Kolker H J; Verweij J; Stoter G; Durante N M; Eggermont A M
Pharmacokinetics of the multidrug-resistance-converting drug dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of tumor-bearing Wag/Rij rats.
Cancer chemotherapy and pharmacology 1997;41(1):48-52.
1997: Gerrits C J; de Jonge M J; Schellens J H; Stoter G; Verweij J
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
British journal of cancer 1997;76(7):952-62.
1997: Gerrits C J; Schellens J H; Creemers G J; Wissel P; Planting A S; Pritchard J F; DePee S; de Boer-Dennert M; Harteveld M; Verweij J
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
British journal of cancer 1997;76(7):946-51.
1997: Planting A; Kho S; van der Burg M; Goey H; Schellens J; van den Bent M; van der Gaast A; de Boer-Dennert M; Stoter G; Verweij J
A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer.
Cancer chemotherapy and pharmacology 1997;40(4):347-52.
1996: Planting A S; van der Burg M E; Goey S H; Schellens J H; Vecht C; de Boer-Dennert M; Stoter G; Verweij J
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic malignant melanoma.
European journal of cancer (Oxford, England : 1990) 1996;32A(11):2026-8.
1996: Creemers G J; Gerrits C J; Schellens J H; Planting A S; van der Burg M E; van Beurden V M; de Boer-Dennert M; Harteveld M; Loos W; Hudson I; Stoter G; Verweij J
Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(9):2540-5.
1996: de Wit R; Beijnen J H; van Tellingen O; Schellens J H; de Boer-Dennert M; Verweij J
Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets.
British journal of cancer 1996;74(2):323-6.
1996: Schellens J H; Ma J; Planting A S; van der Burg M E; van Meerten E; de Boer-Dennert M; Schmitz P I; Stoter G; Verweij J
Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.
British journal of cancer 1996;73(12):1569-75.
1996: Schellens J H; Creemers G J; Beijnen J H; Rosing H; de Boer-Dennert M; McDonald M; Davies B; Verweij J
Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
British journal of cancer 1996;73(10):1268-71.
1996: Loos W J; Stoter G; Verweij J; Schellens J H
Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine.
Journal of chromatography. B, Biomedical applications 1996;678(2):309-15.
1996: van den Bent M J; Schellens J H; Sillevis Smitt P A; Vecht C J
[Chemotherapy in brain tumors]
Nederlands tijdschrift voor geneeskunde 1996;140(13):702-6.
1996: Gerrits C J; Creemers G J; Schellens J H; Wissel P; Planting A S; Kunka R; Selinger K; de Boer-Dennert M; Marijnen Y; Harteveld M; Verweij J
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
British journal of cancer 1996;73(6):744-50.
1996: Schellens J H; Pronk L C; Verweij J
Emerging drug treatments for solid tumours.
Drugs 1996;51(1):45-72.
1996: Van de Vrie W; Schellens J H; Loss W J; Kolker H J; Verwey J; Stoter G; Durante N M; Eggermont A M
Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model.
Journal of cancer research and clinical oncology 1996;122(7):403-8.
1996: Ma J; Stoter G; Verweij J; Schellens J H
Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations.
Cancer chemotherapy and pharmacology 1996;38(4):391-4.
1996: van Warmerdam L J; Creemers G J; Rodenhuis S; Rosing H; de Boer-Dennert M; Schellens J H; ten Bokkel Huinink W W; Davies B E; Maes R A; Verweij J; Beijnen J H
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.
Cancer chemotherapy and pharmacology 1996;38(3):254-60.
1996: Ma J; Verweij J; Planting A S; Kolker H J; Loos W J; de Boer-Dennert M; van der Burg M E; Stoter G; Schellens J H
Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes.
Cancer chemotherapy and pharmacology 1996;37(4):382-4.
1995: Planting A S; van der Burg M E; Goey S H; Schellens J H; van den Bent M J; de Boer-Dennert M; Stoter G; Verweij J
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(6):613-5.
1995: Ma J; Verweij J; Planting A S; de Boer-Dennert M; van Ingen H E; van der Burg M E; Stoter G; Schellens J H
Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.
British journal of cancer 1995;71(3):512-7.
1995: van Warmerdam L J; Verweij J; Schellens J H; Rosing H; Davies B E; de Boer-Dennert M; Maes R A; Beijnen J H
Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.
Cancer chemotherapy and pharmacology 1995;35(3):237-45.
1994: Schellens J H; Planting A S; van Acker B A; Loos W J; de Boer-Dennert M; van der Burg M E; Koier I; Krediet R T; Stoter G; Verweij J
Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.
Journal of the National Cancer Institute 1994;86(12):906-12.
1994: Ma J; Verweij J; Kolker H J; van Ingen H E; Stoter G; Schellens J H
Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.
British journal of cancer 1994;69(5):858-62.
1994: Planting A S; Schellens J H; Goey S H; van der Burg M E; de Boer-Dennert M; Stoter G; Verweij J
Weekly high-dose cisplatin in malignant pleural mesothelioma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(4):373-4.
1994: van Warmerdam L J; Verweij J; Rosing H; Schellens J H; Maes R A; Beijnen J H
Limited sampling models for topotecan pharmacokinetics.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(3):259-64.
1993: Schellens J H; Loos W; Beijnen J H; Stoter G; Verweij J
Sensitive isocratic high-performance liquid chromatographic determination of a novel indoloquinone cytotoxic drug (EO9) in human plasma and urine.
Journal of chromatography 1993;615(2):309-15.

Sign-in to see more